Dechert LLP advised Poxel (Euronext – POXEL – FR0012432516) in its €26.5 million capital increase by institutional investors in the United States and in Europe. Poxel intends to mainly use this capital increase to initiate and progress the Phase 3 Imeglimin program in Japan.

Based in Lyon (France), Poxel is a biopharmaceutical company focused on the development of innovative treatments for type 2 diabetes.

The Dechert team advising Poxel was led by partner François Hellot assisted by Quentin Durand, associate and Patrick Lyons, partner and Amy Rees, associate based in London.

The bank syndicate included Jefferies LLC, Jefferies International Limited, Oddo & Cie, Oppenheimer & Co Inc. and was advised by Gide Loyrette Nouel and Cooley LLP.